The mean suicidal ideation score at post treatment for participants without PTSD was 0.6 (s.d. 1.0), with a mean suicidal ideation intensity rating of 4.1 (s.d. 6.2). For the overall sample, these values were 0.4 (s.d. 0.9) and 3.1 (s.d. 5.6), respectively. 4 illustrates the trajectory and intensity of suicidal ideation, respectively, throughout the study visits. The primary outcome measure was change in MDD symptom severity, as does mdma cause depression and anxiety, or is it a future treatment measured by mean change in MADRS scores from baseline to outcome visit ∼8 weeks after the second MDMA session (∼12 weeks post baseline).

When ingested, psilocybin is converted to psilocin, which then acts as an agonist at several serotonergic and non-serotonergic receptors. Psilocybin has been shown to have low physiological toxicity (i.e., limited negative impacts on physical health) and low abuse potential when orally ingested (35,36). Understanding MDMA’s interaction with serotonin pathways is key to evaluating its immediate neurological effects and potential lasting consequences. MDMA is an amphetamine derivative, capable of crossing the blood–brain barrier to the central nervous system, where its major substrates are the vesicular and presynaptic monoamine transporters Elliott and Beveridge, 2005.

Ayahuasca for Social Anxiety Disorder

• The effects of MDMA may reduce anxiety in the face of emotionally challenging thoughts or memories and can increase self-compassion and enhance fear-extinction learning27,28,29,30.
• Some studies indicate that frequent MDMA users may be at a higher risk of developing depression or anxiety, particularly if the drug is used in high doses or over extended periods.
• Toward this end, recent work in rodents has modeled distinct behavioral processes hypothesized to play a role in MDMA-assisted psychotherapy.
• Such matching is important as some of the behavioural measures in this study were correlated with measures of illicit drug use other than MDMA.

Therefore, there is an urgent need for additional studies with Veteran participants within the VA medical setting, as well as additional studies on P-AT for PTSD and studies with larger, more diverse samples. Human data on changes in Tph typically come from post mortem tissues and these studies lack statistical power. One case report demonstrates that Tph was severely decreased in an autopsied brain of a ‘chronic’ MDMA user. Yet, this report also indicates that the subject took MDMA 4–5 nights per week, for 3 years prior to death and, on the weekend, would ingest 6–8 tablets Kish et al. 2010.

Depression and cognitive function in MDMA users

• This proof of principle study will inform the development of fully powered RCTs, optimize the protocol for the administration of MDMA-AT in participants with MDD and explore uncertainties including barriers to recruitment, retention and acceptability.
• Chelsea Tersavich, PA-C, is a psychiatric clinician who has conducted psychiatric evaluations and facilitated ketamine therapy sessions for over 250 Mindbloom clients.
• While P-AT protocols differ in some ways, administration sessions last an average of 7.46 hours and include at least one preparation and typically about 6 integration sessions (59).
• Regardless of the specific cause of MDMA-related depression, some evidence suggests that long-term MDMA users seem to experience higher levels of depression than those who never use the drug.

For example, other noncompetitive NMDAR antagonists, including memantine and MK-801, either lack antidepressant effects (e.g., memantine) or only have short-lasting effects, which are often inconsistent between studies (e.g., MK-801) (Zanos and Gould, 2018). This suggests that additional, non-NMDAR-mediated effects of ketamine mediate its striking antidepressant action, although the role of subtype specific binding to NMDRs of the different antagonists cannot be ruled out. Participants were excluded if they could not safely taper off psychiatric medications, which was required for study participation. Enrollment was allowed for participants with substance use disorders, if in remission for at least 60 days prior to enrollment. Numerous studies have compiled data from recreational users to investigate the relationship between MDMA and mood in humans. In one self-reported study, it was stated that the feeling of depression post-MDMA exposure in a cohort of 20 ‘ecstasy’ users was 55% Davison and Parrott, 1997.

Understanding MDMA and Its Effects on the Brain

Molly Blues, also referred to as “Tuesday Blues” or “Suicide Tuesdays,” is a term used to describe the depressive state that often follows MDMA use. This condition is characterized by feelings of sadness, anxiety, irritability, and fatigue. Users may experience difficulty concentrating, sleep disturbances, and a general sense of emotional emptiness. To understand the link between MDMA and depression, it’s crucial to examine how this substance affects the brain’s chemistry, particularly its interaction with serotonin.

Does MDMA Cause Depression? Understanding the Link Between MDMA Use and Mental Health

Spearheaded largely by the Multidisciplinary Association of Psychedelic Studies (MAPS), MDMA is currently the closest medicine to receiving FDA approval as a valid therapeutic modality. The brain’s serotonin system temporarily depletes following this rapid release, contributing to the “comedown” phenomenon. This depletion of stored serotonin underlies the temporary depressive symptoms, fatigue, and irritability. The brain requires time to synthesize and replenish its serotonin stores, leading to a period of altered neurochemical balance.

Increased prosocial feelings (57), improved tolerance for unpleasant memories (58) and enhanced empathy and self-compassion (59), can promote a strong therapeutic alliance to effectively process traumatic memories. MDMA produces complex pharmacological effects that may be further influenced by psychotherapy. MDMA promotes neuroplasticity through BDNF and regulates the HPA axis, improving functional outcomes through effects on learning and memory, which are reinforced in the context of psychotherapy. This is the biggest advantage MDMA has over the present-day medication options for treating depression, which typically takes several days to a few weeks to start working. However, decreased appetite (16.7 v. 52.2% in MAPP1) and anxiety (25.0 v. 32.6% in MAPP1) were less frequent.

Although we used MADRS raters who were not part of the therapy team and were unaware of participants’ depression history or present condition, they were neither completely independent nor blinded. As a result, a potential rater bias may have inflated pre–post difference in MADRS scores. It would have been preferable for adverse events to be assessed by an independent adverse event assessor. We did not assess adherence to the MDMA-AT therapy manual,Reference Mithoefer24 which may have resulted in deviations from the manual and variations in the therapeutic support provided. However, the therapists had their adherence rated in a previous MDMA trial,20 with supervision from an experienced MDMA-AT supervisor.

Alongside sessions of supportive psychotherapy, psilocybin administration may help those with PTSD tolerate challenging emotions and address the traumas that they have experienced, while also finding new perspectives on unhelpful or negative thoughts. Rodent and primate studies demonstrate that high-dose or repeated exposure leads to axonal degeneration in serotonergic pathways, particularly in projections from the raphe nuclei. These structural changes correlate with behavioral alterations, including increased anxiety and cognitive deficits.

Similar bills are currently underway in the states of California, Washington, New Jersey, and Massachusetts. The FDA has been reviewing the evidence for P-AT for mental health treatment, which may lead to legalization of P-AT for this purpose (38). Activation of 5-HT1A receptors contributes to relaxation and reduced anxiety, while 5-HT2A receptor stimulation alters perception and enhances emotions. MDMA’s effects vary by brain region—heightened serotonergic activity in the amygdala increases emotional sensitivity, while increased signaling in the prefrontal cortex enhances cognitive flexibility and social bonding.

If demonstrated to be effective and safe in RCTs, MDMA-AT could represent a significant advancement in the treatment of MDD, offering an integrated approach where the drug is used several times to catalyse psychotherapy rather than being administered daily as is the case with antidepressants. We implemented a comprehensive psychotherapeutic regimen in delivering MDMA-AT for MDD. Prior training and experience from a similar MDMA-AT study was important, and team discussions to manage transference, countertransference and other challenges all proved valuable.

The physiological mechanisms for inducing and maintaining ketamine’s lasting effects in humans are not yet understood well enough to design similar therapeutics with improved durability and safety. As previously explained, ketamine’s antidepressant mechanism has long been attributed to antagonism of the NMDAR and to the activation of mTORC1. More recently, clinical trials testing some of the predictions derived from NMDAR-based models have yielded unexpected results (Costi et al., 2019; Abdallah et al., 2020).

MDMA-induced changes in connectivity appear to be restricted to specific regions in the salience network, and not affecting connectivity globally. Other neurochemical and behavioral effects of MDMA include increased oxytocin51, elevated serotonergic activity52, increased self-compassion, and prosocial interactions with others24,28, which can enhance trust and rapport with therapists. Unlike most FDA‐approved drugs that require a chronic daily dosing regimen for efficacy, with maintenance treatment required to prevent relapse, MDMA is administered as two to three single‐dose treatments, frequently with a strong response after the first session. In contrast to maintenance dosing, which can place significant burden on metabolic pathways and increase potential adverse effects, single‐dose treatments have a more favorable risk/benefit profile. Therefore, single‐dose toxicity studies with assessments for delayed toxicity and reversibility after washout appear more appropriate than repeated‐dose toxicology studies. Likewise, pre‐postnatal development studies with daily dosing covering development up to sexual maturity, currently required in all countries to support marketing approval, may be beyond the scope of what should be required to demonstrate safety of single‐dose treatments.